ALK
ALK, or anaplastic lymphoma kinase: a gene that tells your body how to make proteins that help cells talk to each other.
-
NOV 09, 2017 01:30 PM PSTNOV 09, 2017 01:30 PM PSTThe GeneStrat® Genomic Test is a blood-based series of ddPCR tests for DNA (EGFR, KRAS, BRAF) and multiplexed assays for RNA variants (EML4-ALK, ROS1, RET). In this report we will u...Speaker: Hestia Mellert, PhDPresented At:Clinical Diagnostics & Research 2017MAY 24, 2017 12:00 PM PDTMAY 24, 2017 12:00 PM PDTR&D in life science, material science, and chemistry is burdened by fragmented and unstructured data (“spreadsheet hell”), and ambiguous or unrecorded methodological data. Thi...Speaker: Tim GardnerPresented At:Lab Automation 2017SEP 09, 2015 09:00 AM PDTSEP 09, 2015 09:00 AM PDTDATE: September 9, 2015TIME: 9:00am PDT, 12:00PM EDTDriver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as ...JUN 10, 2015 02:00 PM PDTJUN 10, 2015 02:00 PM PDTMatching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...Speaker: Stephen Lyle, MD, PhDPresented At:Cardinal Health labXchangeSEP 16, 2014 10:00 AM PDTSEP 16, 2014 10:00 AM PDTPatients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small c...Speaker: Sean Eddy, PhDSEP 16, 2014 09:30 AM PDTSEP 16, 2014 09:30 AM PDTLate-stage drug attrition rates in oncology remain higher than in other therapeutic areas. To reduce attrition, it is critical to identify appropriate drug targets and pre-clinical models. Th...Speaker: Nickolay Khazanov, PhDOCT 16, 2013 02:00 PM PDTC.E. CREDITSOCT 16, 2013 02:00 PM PDTNon Small Cell Lung Cancer (NSCLC) is one of the most significant causes of cancer-related mortality worldwide. In about 6-7% of NSCLC, rearrangements involving the Anaplastic Lymphoma Kinase...Speaker: Roberto Chiarle, MDPresented At:Cancer: Research, Discovery and Therapeutics 2013
NOV 09, 2017
01:30 PM PST
NOV 09, 2017
01:30 PM PST
The GeneStrat® Genomic Test is a blood-based series of ddPCR tests for DNA (EGFR, KRAS, BRAF) and multiplexed assays for RNA variants (EML4-ALK, ROS1, RET). In this report we will u...
Speaker:
Hestia Mellert, PhD
Presented At:Clinical Diagnostics & Research 2017
MAY 24, 2017
12:00 PM PDT
MAY 24, 2017
12:00 PM PDT
R&D in life science, material science, and chemistry is burdened by fragmented and unstructured data (“spreadsheet hell”), and ambiguous or unrecorded methodological data. Thi...
Speaker:
Tim Gardner
Presented At:Lab Automation 2017
SEP 09, 2015
09:00 AM PDT
SEP 09, 2015
09:00 AM PDT
DATE: September 9, 2015TIME: 9:00am PDT, 12:00PM EDTDriver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as ...
JUN 10, 2015
02:00 PM PDT
JUN 10, 2015
02:00 PM PDT
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
Speaker:
Stephen Lyle, MD, PhD
Presented At:Cardinal Health labXchange
SEP 16, 2014
10:00 AM PDT
SEP 16, 2014
10:00 AM PDT
Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small c...
Speaker:
Sean Eddy, PhD
SEP 16, 2014
09:30 AM PDT
SEP 16, 2014
09:30 AM PDT
Late-stage drug attrition rates in oncology remain higher than in other therapeutic areas. To reduce attrition, it is critical to identify appropriate drug targets and pre-clinical models. Th...
Speaker:
Nickolay Khazanov, PhD
OCT 16, 2013
02:00 PM PDT
C.E. CREDITS
OCT 16, 2013
02:00 PM PDT
Non Small Cell Lung Cancer (NSCLC) is one of the most significant causes of cancer-related mortality worldwide. In about 6-7% of NSCLC, rearrangements involving the Anaplastic Lymphoma Kinase...
Speaker:
Roberto Chiarle, MD
Presented At:Cancer: Research, Discovery and Therapeutics 2013